IRadimed Corp

The stock has decisively broken its key support zone on strong volume, indicating that sellers are firmly in control. Price sits below the 9, 20, and 50 EMAs, confirming negative momentum in the near term. The medium-term structure favors further downside continuation after the support failure. Short-term conditions align with immediate execution readiness for bearish positioning, despite the long-term trend remaining structurally bullish.

• ↑Q1 2026 revenue reached $22 M, a 13% YoY gain on 3870 pump ramp
• ↑Gross margin of 77% reflects strong profitability and cost control
• ↓Negative earnings yield may indicate valuation stretched without growth